- Advertisement -

Pfizer Inc. disclosed the price it expects in the US for its adult COVID-19 vaccine in the commercial market.

Ticker Safety Last Change Change %
PFE PFIZER INC. 44.98 +2.08 +4.85%
- Advertisement -

The Pfizer-BioNTech vaccine will potentially cost between $110 and $130 for a single-dose vial in the US, Pfizer’s Angela Lukin said in a call with an analyst and investor.

That cost will reflect its “cost-effectiveness,” including the “increase in costs” associated with moving from a multi-dose vial to single-dose and commercial distribution, as well as the value it “brought to society,” Lukin said. .

- Advertisement -

PFIZER SEEKS APPROVAL OF OMICRON BOOSTER FOR CHILDREN OVER 5 YEARS

At the end of June, the federal government struck a deal with Pfizer and BioNTech SE to supply 105 million doses of the COVID-19 vaccine worth $3.2 billion, the equivalent of what the US pays roughly $30 per dose.

Since then, the Department of Health and Human Services has said it has plans to abandon its vaccine procurement program and move vaccines to the commercial market, according to the Wall Street Journal.

COVID-19 vaccine

Lukin noted that Pfizer’s transition to the traditional commercial market is dependent on factors such as government supplies and will not happen until Q1 2023 “at the earliest.”

PFIZER TO SUPPLY UP TO 6 MILLION COVID-19 TREATMENTS FOR LOWER-INCOME COUNTRIES

The company’s goal, she said, is to “continue equitable and uninterrupted access” to its COVID-19 vaccine and “accessibility to the healthcare system.”

Pfizer vaccine for COVID

“Based on our current understanding, when we enter the traditional commercial model, anyone who has commercial or government insurance and is eligible for vaccination should have access to the vaccine without any out-of-pocket payments,” she said.

“This suggests continuing broad recommendations in support of annual vaccination.”

CDC APPROVES UPDATED COVID-19 VACCINES AIMED FOR OMICRON VACCINE

As of June, Pfizer has distributed more than 3.5 billion doses of the COVID-19 vaccine. according to company newsletter.